Shannon Heaning, Content Associate

A biopsy-based analysis from the JADE MOA trial presented at EADV 2026 found reductions in pathogenic skin-resident memory T cells alongside restoration of epidermal barrier integrity.

This week’s review highlights pediatric oral minoxidil guidance, alopecia areata imaging, inherited skin disorder growth patterns, total-body photography, and radiofrequency microneedling for rosacea.

Celltrion’s US launch of omalizumab-igec adds an interchangeable biosimilar option for eligible patients with chronic spontaneous urticaria.

Andrew Blauvelt, MD, MBA, discusses how to interpret head-to-head, indirect, and long-term efficacy data for emerging oral psoriasis therapies.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

New exploratory findings on disease duration and tunnel outcomes offer a starting point for conversations about comprehensive hidradenitis suppurativa care.

Explore dermatology conferences and meetings taking place this October, including clinical updates, skin of color education, and pediatric dermatology research.

New indications for superficial basal cell carcinoma and adolescent alopecia areata expanded treatment options, while psoriasis and rare disease candidates advanced through FDA review.

From next-generation oral therapies and long-term disease control to precision medicine, EADV 2026 highlighted a dermatology landscape increasingly focused on deeper, durable, and individualized outcomes.

The final day of EADV 2026 explored precision medicine, molecular profiling, atopic dermatitis research, real-world evidence, and emerging approaches to individualized dermatologic care.

New EADV 2026 data highlighted real-world outcomes in adults with chronic hand eczema and improvements in itch, pain, and quality of life among adolescents treated with delgocitinib cream.

Adam Friedman, MD, discusses PsA screening, comorbidities, early systemic intervention, and individualized oral therapy selection in psoriasis.

Day 3 of EADV 2026 featured long-term psoriasis data, advances in hidradenitis suppurativa, evolving approaches to atopic dermatitis, and late-breaking research.

Seven presentations will highlight phase 3 maintenance and induction findings, 3-year phase 2 data, and preclinical research evaluating obefazimod in ulcerative colitis.

Updated phase 2 results from the AMETHYST study showed continued improvements in skin disease activity through 52 weeks, with more than one-quarter of patients achieving clear or almost clear skin.

Christophe Piketty, MD, PhD, discussed 3-year findings from the ARCADIA long-term extension study and the implications of targeting IL-31 in atopic dermatitis.

Phase 2b REZOLVE-AA data presented at EADV 2026 showed sustained and deepening hair regrowth following treatment cessation.

Michael Payette, MD, discusses systemic psoriasis treatment, patient selection, special-site disease, and shared decision-making.

Phase 3 LATITUDE Atlas data presented at EADV 2026 showed higher rates of complete and near-complete skin clearance with zasocitinib compared with deucravacitinib.

Day 2 of EADV 2026 highlighted new findings involving GLP-1–associated nail changes, long-term atopic dermatitis control, emerging therapies, alopecia, and hidradenitis suppurativa.

Phase 2b SPOTLIGHT-204 results presented at EADV 2026 showed complete clinical and pathological responses in more than half of patients with high-risk head and neck basal cell carcinoma.

Real-world EADV 2026 data suggest autonomous AI could increase dermatology capacity while maintaining high sensitivity for invasive skin cancers.

New phase 2 data presented at EADV 2026 demonstrated significant improvements in disease activity with daxdilimab, with responses emerging as early as week 4.

Late-breaking EADV 2026 data showed significant improvements in skin clearance, itch, pain, and patient satisfaction among patients treated with lebrikizumab.

Day 1 of EADV 2026 brought new data across atopic dermatitis, cutaneous lupus, skin cancer, AI, climate-related skin disease, and more.

Two studies presented at EADV 2026 highlight misinformation and dermatologic complications linked to viral skincare routines on social media.

Phase 2 data presented at EADV 2026 showed daxdilimab significantly reduced disease activity and improved response rates in treatment-refractory DLE.

This review of the latest dermatological studies includes insights on ruxolitinib for lichen planus, early vitiligo treatment, psoriasis response, AD disease control, and PFB management.

EADV 2026 data highlight dupilumab’s effects on growth, quality of life, disease control, and itch across multiple dermatologic diseases.

Dermatology Times is looking back on the top stories in dermatology from the month of September.